Fortress Biotech, Inc. (NASDAQ: FBIO) is a Healthcare company (Biotechnology) with a market capitalization of $61M. The Maz Rating grades it against the other companies in its sector.
Fortress Biotech, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.82, Fortress Biotech, Inc. trades at 0.6x trailing earnings, 0.9x sales and 0.4x book value. Over the last twelve months it generated about $70M of revenue and $97M of net income. It runs a gross margin of 63.2%, an operating margin of -42.5% and a net margin of 143.0%. It shows return on equity of 74.7%, return on invested capital of -13.1% and a free cash flow yield of 206.6%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 2.93. Over the past 52 weeks the share price ranged from $1.64 to $4.53, with a beta of 1.25.
Fortress Biotech, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Fortress Biotech, Inc. (FBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 38.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 251.6% / 30% · Interest income / Revenue 6.76% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 38.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 210.8% / 33% · Receivables / Mkt Cap (36m) 65.6% / 49% · Interest income / Revenue 6.76% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 38.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 210.8% / 33.33% · Receivables / Mkt Cap (24m) 65.6% / 33.33% · Interest income / Revenue 6.76% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 15.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 60.0% / 33.33% · Receivables / Avg Assets (4Q) 12.3% / 33.33% · Interest income / Revenue 6.76% / 5% | Fail |
| FTSE | Debt / Total Assets 10.0% / 33.33% · (Cash+ST Inv) / Total Assets 54.3% / 33.33% · (Cash+Recv) / Total Assets 71.2% / 33.33% · Interest income / Revenue 6.76% / 5% | Fail |
No. As of September 2026, Fortress Biotech, Inc. (FBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Fortress Biotech, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m), (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 6.76% of each dividend: Fortress Biotech, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.